I. Introduction
Heart failure (HF) is a serious medical condition resulting in a considerably increased risk of premature death and decreased quality of life. The prevalence of heart failure in Sweden is around 2% [1]. A majority of the patients are elderly. At the age of 80 or above, the prevalence is more than 10%. Proper medication can substantially improve the conditions for many heart failure patients and is in many cases essential for reducing the risk of premature death. At the same time, prescribing patterns for many older patients are affected by co-morbidity and polypharmacy [2]. In a study by Zarrinkoub and others [1], more than 50% of the patients were of age 80 or above in year 2010.